Warning letter
Siddha Flower Essences, LLC., dba Siddha Remedies: warning letter of Nov 4, 2025
FDA warning letter 713217 · Center for Drug Evaluation and Research (CDER)
Key facts
| Reference number | 713217 |
|---|---|
| Company | Siddha Flower Essences, LLC., dba Siddha Remedies |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Nov 4, 2025 |
| Posted date | Nov 18, 2025 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| Product type | Drugs |
| CFR sections cited | 207.57(b), 207.57(b)(2), 207, 211.22, 211.22(a), 211.22(d), 211.34, 211.84(d)(1), 211.84(d)(6), 211.100(a), 211.160(b), 211.165(b) and 1 more |
| Inspection city | Oxnard |
| Inspection ZIP | 93030 |
| Inspection start date | Apr 22, 2025 |
| Letter on fda.gov | fda.gov |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: